Cannabis is often labeled addictive, but the science tells a more precise story. This piece breaks down cannabis use disorder, how it is defined, and why mild, moderate, and severe cases get flattened into one fear-driven narrative. The result is a distorted public understanding of risk that fuels policy, perception, and misinformation.
Australia Cracks Down on Medical Cannabis
Australia’s medical cannabis system expanded rapidly through telehealth and high-volume prescribing. Now regulators are tightening oversight. The TGA and AHPRA are increasing scrutiny on prescribing practices, signaling a shift from rapid patient access toward stricter clinical control that could reshape how doctors prescribe and how patients obtain treatment.
IDAHO TRIES TO STOP A VOTE BEFORE IT STARTS
Idaho lawmakers passed a resolution urging voters to reject a medical cannabis initiative before it reaches the ballot. The move highlights how officials are shaping public opinion ahead of a vote, while maintaining strict prohibition and blocking even limited access for patients.
MS LIMITS MEDICAL CANNABIS WHERE IT MATTERS MOST
Mississippi maintains strict limits on medical cannabis after Governor Tate Reeves vetoed expansion bills on March 26, 2026. Patients remain unable to use cannabis in hospitals while eligibility and access rules stay tightly controlled. This feature examines what the veto blocks, how it affects patients, and what it means for the state’s growing cannabis market.
Thailand Lost Control
Thailand blew open its cannabis market, then tried to force it back under control. This feature tracks the country’s shift from prohibition to medical legalization, decriminalization, and regulatory backlash, exposing how weak enforcement, political pressure, and rushed policy turned a reform headline into a live case study in state correction.
Texas Is Moving to Shut Down the Hemp Market
Texas helped build one of the largest hemp THC markets in the country, then moved to shut it down. As regulators tighten rules and enforcement increases, businesses are left exposed, and the future of hemp-derived cannabinoids hangs in the balance. This is not a simple crackdown. It is a full policy reversal with real economic consequences.